REGENXBIO Inc.
RGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -7.7% | -19.9% | -76% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.7% | 58.8% | 51.6% | 89% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -237.9% | -265.4% | -216.7% | 36% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -272.5% | -292% | -248.7% | 27.2% |
| EPS Diluted | -4.59 | -6.02 | -6.5 | 2.91 |
| % Growth | 23.8% | 7.4% | -323.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |